Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease · HIV-Associated Neurocognitive Disorder

Treatment Strategy and Managing Medication

At a Glance

The main treatment for HIV-associated neurocognitive disorder is consistent antiretroviral therapy that keeps HIV suppressed. If symptoms continue, clinicians assess CSF viral escape, medication effects, mental health, sleep, vascular risks, and rehabilitation needs.

Treating HIV-Associated Neurocognitive Disorder (HAND) is not about finding a single “miracle pill.” Instead, it is a comprehensive strategy focused on keeping the virus under control while managing every other factor that affects your brain health [1][2]. There is currently no medication proven to completely reverse HAND itself, but treating the whole picture can significantly improve your function.

The Foundation: Viral Suppression

The most important treatment for your brain is the same as the treatment for your body: Antiretroviral Therapy (ART). The goal is to keep your viral load “undetectable” [2].

  • Consistent Adherence: Taking your medication exactly as prescribed helps suppress the virus in your blood and often your central nervous system, though it is not a complete guarantee that you won’t have symptoms [3].
  • Safety Warning: Do NOT stop or change your ART, supplements, antidepressants, sedatives, or other medications without discussing the change with your clinician.

Addressing “CSF Viral Escape”

In some cases, the HIV virus can “escape” into the cerebrospinal fluid (CSF) (the fluid around your brain), even when your blood tests look perfect [4][5]. If your cognitive symptoms are getting worse despite an undetectable blood viral load, your doctor may perform a lumbar puncture to check for this escape [5].

If escape is found and there is enough virus to test, the solution is not to guess which drugs might work better. Your doctor should perform resistance testing on the virus in your spinal fluid [6][7]. This allows them to optimize your ART regimen based on exactly which drugs will be most effective, while factoring in your adherence, drug interactions, and overall health [6].

Avoiding Common Myths

There are several misunderstandings about HAND treatment that you should discuss with your care team:

  • The “CPE Score” Myth: You may hear about CNS Penetration-Effectiveness (CPE) scores—a system that ranks HIV drugs by how well they get into the brain. While it sounds logical to switch to drugs with higher scores, recent evidence shows this is not recommended [4][8]. Choosing a drug based only on its score can lead to treatment failure if it doesn’t match your virus’s resistance profile [4][9].
  • Unproven Add-on Drugs: Many drugs have been studied to see if they can “boost” brain power in people with HIV, including memantine, minocycline, and selegiline. To date, none of these have been proven to treat HAND effectively in clinical trials [10][11].

The “Whole-Person” Approach

Because cognitive changes are often multifactorial (caused by many things), managing your brain health means:

  • Treating Comorbidities: High blood pressure, diabetes, and high cholesterol can all damage brain health. Controlling these vascular risks is a vital part of protecting your memory [12][13]. Reviewing sedating or anticholinergic medicines, screening for sleep apnea, and addressing vision/hearing problems and substance use are also critical.
  • Addressing Mental Health: Depression and anxiety can cause significant cognitive fog and often coexist with HAND. Treating these conditions with therapy or medication can often help improve the fog, even if it doesn’t clear it completely [14][15]. (If your depression becomes severe or you have thoughts of self-harm, please reach out to your local emergency or crisis hotline immediately.)
  • Lifestyle Factors: Using occupational/cognitive rehabilitation and adapting your lifestyle can help you stay independent [16][17].

By focusing on all these areas together, you can create the best environment for your brain to stay healthy and resilient [2][18].

Common questions in this guide

What is the main treatment for HIV-associated neurocognitive disorder?
The foundation is taking antiretroviral therapy exactly as prescribed to keep HIV suppressed and the blood viral load undetectable. ART may not completely reverse HAND or guarantee that cognitive symptoms disappear, so clinicians also look for other treatable causes of brain fog.
Should I change my HIV medicines to get a higher CPE score?
No. Changing ART solely to pursue a higher CNS Penetration-Effectiveness score is not recommended because the best regimen depends on viral resistance, adherence, drug interactions, and overall health. Ask your clinician to evaluate whether your current treatment is controlling HIV before making any change.
What is CSF viral escape, and how is it tested?
CSF viral escape occurs when HIV is detectable in the fluid around the brain even though the blood viral load is undetectable. If cognitive symptoms worsen, a clinician may consider a lumbar puncture to test the CSF; if enough virus is present, resistance testing can help select effective ART.
Can memantine, minocycline, or selegiline treat HAND?
These drugs have been studied as add-on treatments, but clinical trials have not shown them to be effective treatments for HAND. Do not start, stop, or change these or any other medicines without discussing the decision with your clinician.
What else can help with brain fog related to HAND?
Managing blood pressure, diabetes, and cholesterol; reviewing sedating or anticholinergic medicines; checking for sleep apnea; addressing hearing, vision, and substance use; and treating depression or anxiety may help. Occupational or cognitive rehabilitation can also support daily functioning and independence.
What should I do if depression becomes severe or I have thoughts of self-harm?
If you have thoughts of self-harm or feel unsafe, contact local emergency services or a crisis hotline now and tell someone you trust; do not wait for a routine appointment. Severe depression should also be discussed promptly with your healthcare clinician.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Dementia associated with AIDS.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my HIV viral load still undetectable in my blood, and if so, is there a clinical reason to test my spinal fluid for 'CSF escape'?
  2. 2.Instead of changing my HIV meds for a better 'CPE score,' can we check if my current regimen is actually failing to control the virus?
  3. 3.How are we managing my other health issues, like blood pressure or depression, as part of my brain health treatment plan?
  4. 4.Are there any specific exercises or cognitive rehabilitation programs you recommend to help with my daily tasks?
  5. 5.What should I do immediately if my depression becomes severe or I experience thoughts of self-harm?

References

References (18)
  1. 1

    Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis.

    Wang Y, Liu M, Lu Q, et al.

    Neurology 2020; (95(19)):e2610-e2621 doi:10.1212/WNL.0000000000010752.

    PMID: 32887786
  2. 2

    Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.

    Sacktor N, Saylor D, Nakigozi G, et al.

    Journal of acquired immune deficiency syndromes (1999) 2019; (81(2)):216-223 doi:10.1097/QAI.0000000000001992.

    PMID: 30865184
  3. 3

    Impact of HIV-associated cognitive impairment on functional independence, frailty and quality of life in the modern era: a meta-analysis.

    Nweke M, Mshunqane N, Govender N, et al.

    Scientific reports 2022; (12(1)):6470 doi:10.1038/s41598-022-10474-8.

    PMID: 35440802
  4. 4

    HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives.

    Kelly SH, Nightingale S, Gupta RK, Collier DA

    Tropical medicine and infectious disease 2025; (10(2)) doi:10.3390/tropicalmed10020045.

    PMID: 39998049
  5. 5

    Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.

    Filippidis P, Damas J, Viala B, et al.

    Journal of acquired immune deficiency syndromes (1999) 2023; (93(3)):219-228 doi:10.1097/QAI.0000000000003189.

    PMID: 36927958
  6. 6

    Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India.

    Dravid AN, Gawali R, Betha TP, et al.

    Medicine 2020; (99(24)):e20516 doi:10.1097/MD.0000000000020516.

    PMID: 32541474
  7. 7

    Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.

    Dravid AN, Natrajan K, Kulkarni MM, et al.

    Medicine 2018; (97(8)):e9969 doi:10.1097/MD.0000000000009969.

    PMID: 29465595
  8. 8

    The effect of antiretroviral therapy with high central nervous system penetration on HIV-related cognitive impairment: a systematic review and meta-analysis.

    Webb AJ, Borrelli EP, Vyas A, et al.

    AIDS care 2023; (35(11)):1635-1646 doi:10.1080/09540121.2022.2098231.

    PMID: 35850626
  9. 9

    Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.

    Santos GMA, Locatelli I, Métral M, et al.

    Open forum infectious diseases 2019; (6(7)):ofz277 doi:10.1093/ofid/ofz277.

    PMID: 31304188
  10. 10

    Treating HIV Infection in the Central Nervous System.

    Calcagno A, Di Perri G, Bonora S

    Drugs 2017; (77(2)):145-157 doi:10.1007/s40265-016-0678-9.

    PMID: 28070871
  11. 11

    Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review.

    Bougea A, Spantideas N, Galanis P, et al.

    Therapeutic advances in infectious disease 2019; (6()):2049936119838228 doi:10.1177/2049936119838228.

    PMID: 31001421
  12. 12

    Changing clinical phenotypes of HIV-associated neurocognitive disorders.

    Sacktor N

    Journal of neurovirology 2018; (24(2)):141-145 doi:10.1007/s13365-017-0556-6.

    PMID: 28752495
  13. 13

    Uncovering gaps in HIV care in belgium through patient reported outcome measures and neurocognitive screening.

    Vanden Bulcke C, Delesie L, Degroote S, et al.

    Discover mental health 2026; (6(1)).

    PMID: 42176129
  14. 14

    The comorbidity of depression and neurocognitive disorder in persons with HIV infection: call for investigation and treatment.

    Goodkin K, Evering TH, Anderson AM, et al.

    Frontiers in cellular neuroscience 2023; (17()):1130938 doi:10.3389/fncel.2023.1130938.

    PMID: 37206666
  15. 15

    Mindfulness-Based Stress Reduction for Symptom Management in Older Individuals with HIV-Associated Neurocognitive Disorder.

    Moskowitz JT, Sharma B, Javandel S, et al.

    AIDS and behavior 2024; (28(6)):1811-1821 doi:10.1007/s10461-024-04295-1.

    PMID: 38493283
  16. 16

    Two-year clinical trial examining the effects of speed of processing training on everyday functioning in adults with human immunodeficiency virus-associated neurocognitive disorder (HAND) and borderline HAND in the U.S. Deep South: Findings of the Think Fast Study.

    Vance DE, Fazeli PL, Azuero A, et al.

    Applied neuropsychology. Adult 2025; (32(3)):747-760 doi:10.1080/23279095.2023.2209900.

    PMID: 37200482
  17. 17

    A 2-Year, Randomized, Clinical Trial Examining the Effects of Speed of Processing Cognitive Training on Quality-of-Life Indicators in Adults With HIV-Associated Neurocognitive Disorder in Birmingham, Alabama: Results of the Think Fast Study.

    Vance DE, Fazeli PL, Azuero A, et al.

    The Journal of the Association of Nurses in AIDS Care : JANAC 2024; (35(2)):104-121 doi:10.1097/JNC.0000000000000449.

    PMID: 38949906
  18. 18

    Neuropathogenesis of human immunodeficiency virus infection.

    Sillman B, Woldstad C, Mcmillan J, Gendelman HE

    Handbook of clinical neurology 2018; (152()):21-40 doi:10.1016/B978-0-444-63849-6.00003-7.

    PMID: 29604978

This page explains treatment strategies for HIV-associated neurocognitive disorder for informational purposes only and does not constitute medical advice. Do not change HIV or other medicines without discussing your specific situation with your clinician.